-
Dacarbazine meda powder for solution for injection infusion – Change to required period of contraception for female patients
Feb 29, 2024, 14:36 -
Osteomel Once Weekly 70 mg tablets – PA0126/148/002 –10 batches
Feb 28, 2024, 12:50 -
Paxlovid (nirmatrelvir; ritonavir) – Reminder of life-threatening and fatal drug-drug interactions
Feb 21, 2024, 00:00 -
Valproate (Epilim) – Potential risk of NDD in children of fathers treated with valproate
Feb 19, 2024, 00:00 -
Hypovase 0.5 mg tablets – Deletion of all indications of paediatric use of prazosin
Feb 16, 2024, 14:28 -
Pseudoephedrine – Risks of PRES and RCVS
Feb 9, 2024, 00:00 -
PRAC meeting highlights 5-8 February 2024
Feb 5, 2024, 00:00 -
Pinadone 1mg/ml Oral Solution – PA281/61/1 – One batch
Jan 29, 2024, 10:04 -
PRAC meeting highlights 8-11 January 2024
Jan 8, 2024, 00:00 -
CFTR Inhibitors – MIMS – Risk of depression and related events
Jan 1, 2024, 00:00 -
Drug Safety Newsletter – Edition 114 – 21 December 2023
Dec 21, 2023, 00:00 -
Topiramate – MIMS – New Pregnancy prevention programme and new restrictions on use
Dec 1, 2023, 00:00 -
PRAC meeting highlights 27-30 November 2023
Nov 27, 2023, 00:00 -
Omega-3-acid ethyl esters – Dose-dependent increased risk of atrial fibrillation in certain patients
Nov 8, 2023, 00:00 -
Drug Safety Newsletter – Edition 113 – 3 November 2023
Nov 3, 2023, 00:00 -
Paracetamol – MIMS – Monitoring risk factors for hepatotoxicity in patients
Nov 1, 2023, 00:00 -
Montelukast – MIMS – New boxed warning on the risk of neuropsychiatric events
Nov 1, 2023, 00:00 -
Topamax (topiramate) – Restrictions to prevent exposure during pregnancy
Nov 1, 2023, 00:00 -
PRAC meeting highlights 23-26 October 2023
Oct 23, 2023, 00:00 -
Various products – Labelling requirements for veterinary medicines
Oct 16, 2023, 16:36
